Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FCER2 | P06734 | 3/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.33 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.32 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25708078 | 0.85 | FCER2 (0.45) | FCER2SLC7A5ANPEPRNPEPSCN9A | |
| SCHEMBL27263098 | 0.81 | ACE (0.35) | FCER2 | |
| SCHEMBL19749318 | 0.81 | NPY4R (0.49) | — | |
| SCHEMBL21553675 | 0.80 | MAPT (0.36) | FCER2GLO1SCN9A | |
| SCHEMBL5270305 | 0.79 | SLC7A5 (0.48) | SLC7A5ANPEPRNPEPDNPEPLARS1 | |
| SCHEMBL5509836 | 0.79 | SLC7A5 (0.48) | SLC7A5ANPEPRNPEPDNPEPLARS1 | |
| SCHEMBL11788120 | 0.78 | SLC7A5 (0.41) | MMP8SLC7A5ANPEPRNPEPDNPEP | |
| SCHEMBL11788108 | 0.78 | SLC7A5 (0.41) | MMP8SLC7A5ANPEPRNPEPDNPEP | |
| SCHEMBL31339432 | 0.78 | MMP8 (0.46) | MMP8SLC7A5GLO1EGFR | |
| SCHEMBL26777231 | 0.78 | TLR2 (0.38) | FCER2MMP8EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365627-A1 | MACROCYCLIC PEPTIDE BORONATE IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230183292-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2021226460-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365627-A1 | MACROCYCLIC PEPTIDE BORONATE IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | FCER2 1736/4885MMP8 4295/4885SLC7A5 2197/4885 |
| US-20230183292-A1 | IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | FCER2 236/4885MMP8 2581/4885SLC7A5 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.